Meyer Cancer Center, Weill Cornell Medical College, New York, NY 10021;
Department of Pharmacology, Weill Cornell Medical College, New York, NY 10021.
Proc Natl Acad Sci U S A. 2019 Sep 24;116(39):19523-19529. doi: 10.1073/pnas.1902397116. Epub 2019 Sep 6.
The mTORC1 pathway regulates cell growth and proliferation by properly coupling critical processes such as gene expression, protein translation, and metabolism to the availability of growth factors and hormones, nutrients, cellular energetics, oxygen status, and cell stress. Although multiple cytoplasmic substrates of mTORC1 have been identified, how mTORC1 signals within the nucleus remains incompletely understood. Here, we report a mechanism by which mTORC1 modulates the phosphorylation of multiple nuclear events. We observed a significant nuclear enrichment of GSK3 when mTORC1 was suppressed, which promotes phosphorylation of several proteins such as GTF2F1 and FOXK1. Importantly, nuclear localization of GSK3 is sufficient to suppress cell proliferation. Additionally, expression of a nuclear exporter of GSK3, FRAT, restricts the nuclear localization of GSK3, represses nuclear protein phosphorylation, and prevents rapamycin-induced cytostasis. Finally, we observe a correlation between rapamycin resistance and FRAT expression in multiple-cancer cell lines. Resistance to Food and Drug Administration (FDA)-approved rapamycin analogs (rapalogs) is observed in many tumor settings, but the underling mechanisms remain incompletely understood. Given that FRAT expression levels are frequently elevated in various cancers, our observations provide a potential biomarker and strategy for overcoming rapamycin resistance.
mTORC1 途径通过适当结合关键过程(如基因表达、蛋白质翻译和代谢)与生长因子和激素、营养物质、细胞能量、氧状态和细胞应激的可用性,来调节细胞生长和增殖。尽管已经鉴定出 mTORC1 的多种细胞质底物,但 mTORC1 在核内的信号传递仍不完全清楚。在这里,我们报告了 mTORC1 调节多种核事件磷酸化的一种机制。我们观察到当 mTORC1 被抑制时,GSK3 大量富集到核内,这促进了 GTF2F1 和 FOXK1 等多种蛋白质的磷酸化。重要的是,GSK3 的核定位足以抑制细胞增殖。此外,GSK3 的核输出蛋白 FRAT 的表达限制了 GSK3 的核定位,抑制了核蛋白磷酸化,并阻止了雷帕霉素诱导的细胞停滞。最后,我们在多种癌细胞系中观察到雷帕霉素耐药性与 FRAT 表达之间的相关性。在许多肿瘤环境中观察到对美国食品和药物管理局 (FDA) 批准的雷帕霉素类似物(rapalogs)的耐药性,但潜在机制仍不完全清楚。鉴于 FRAT 表达水平在各种癌症中经常升高,我们的观察结果为克服雷帕霉素耐药性提供了一个潜在的生物标志物和策略。